The actual status and the progress of chemotherapy for adults with refractory/relapsed acute myeloid leukemia (except M3)
10.3760/cma.j.issn.1009-9921.2015.04.019
- VernacularTitle:成年人复发难治性急性髓系白血病(M3除外)的化疗方案及其研究进展
- Author:
Xiaoyu LI
;
Min LIN
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Refractory;
Relapsed;
Chemotherapy
- From:
Journal of Leukemia & Lymphoma
2015;24(4):251-253
- CountryChina
- Language:Chinese
-
Abstract:
Although intensive chemotherapy and hematopoietic stem cell transplant (HSCT) are currently used in the treatment of acute myeloid leukemia (AML),a large proportion of patients relapse after treatment.On the other hand,a minority of cases fail to achieve complete remission (CR) after a standard first line treatment.Leukemia relapse and refractory become the main course of treatment failure,which are also the main points and difficulties of treatment for AML.However,the most effective regimen for refractory/relapsed AML has not been established.This review focuses on the progress of the regimens and major chemotherapy for refractory/relapsed AML (except M3).
